The effect of smoking on androgen levels is important given the recent interest in the link between low levels of androgens and the development of cardiovascular disease. Numerous studies examining the effects of cigarette smoking on the levels of total and free testosterone have reported conflicting findings, but there has been no accurate assessment of the effects of cigarette smoking on the levels of bioavailable testosterone [not bound to sex hormone-binding globulin (SHBG)]. We attempted to determine whether smoking affects the level of bioavailable testosterone. We undertook a case-control study of 25 healthy male smokers and 25 healthy never-smokers, matched by age and body mass index. Early morning levels of total, free and bioavailable testosterone, 17β-oestradiol, SHBG and cotinine were determined and compared between the two groups. Levels of total (18.5p4.6 nM versus 15.1p4.9 nM, P l 0.01) and free testosterone (462p91 pM versus 402p93 pM, P l 0.03) were found to be higher in smokers compared with non-smokers respectively, as was SHBG (34.1p12.8 versus 28.1p9.0 nM, P l 0.06). There were no significant differences in the levels of bioavailable testosterone (3.78p1.59 versus 3.51p1.26 nM, P l 0.49) or 17β-oestradiol (44.5p11.4 versus 42.3p11.5 pM, P l 0.50) between smokers and non-smokers respectively. These data suggest that cigarette smoking has no significant effect on the biologically active fraction of testosterone, but may influence the levels of total and free testosterone through changes in the levels of SHBG.
INTRODUCTION
The results of previous studies describing the effects of cigarette smoking on testosterone levels in human males have been conflicting, demonstrating that testosterone levels are lower [1, 2] , similar [3] [4] [5] [6] [7] [8] or higher [9] [10] [11] [12] [13] [14] in healthy male smokers than in matched non-smokers. However, the effects of cigarette smoking on the levels of bioavailable testosterone are unknown.
There is increasing interest surrounding the link between low levels of male sex hormones and coronary artery disease in men. A number of studies have reported lower levels of androgens in cases with coronary heart disease compared with disease-free controls [15] , this relationship being particularly marked when the levels of bioavailable testosterone are assessed [16] . The effects of an excess of smokers in groups with coronary artery disease compared with controls in these studies may be an important confounding factor, with the demonstrated differences in levels of testosterone being only a consequence of cigarette smoking, not a risk factor for coronary heart disease itself.
The aim of the present study was to determine whether the biologically active fraction of testosterone differs in healthy male smokers and non-smokers, since a significant effect of smoking on androgen levels may confound association studies between levels of testosterone and coronary artery disease.
METHODS

Study design
This was a case-control study undertaken in a teaching hospital with the approval of the local ethics committee. Healthy volunteers were recruited from hospital visitors and staff by posting advertisements in the hospital. Smokers were matched to never-smokers of similar age and body mass index. Subjects were studied between 08.00 h and 09.30 h.
Subjects
A total of 25 male smokers of 10 cigarettes\day and 25 males who had never smoked (aged 17-60 years) were recruited. Volunteers were excluded if they had debilitating illness, diabetes mellitus, a history of infertility or hormone-manipulating therapy. Two cases and one control had mild asthma and two controls had hypertension. Junior doctors were excluded from the study since previous research [17] suggests they may have abnormal androgen levels.
Measurements
Height and weight were measured, and blood was taken for analysis of levels of serum total testosterone, bioavailable testosterone, sex hormone-binding globulin (SHBG), 17β-oestradiol and cotinine (a metabolite of nicotine). Free testosterone was calculated as a percentage of the total testosterone by a validated method [18] , using the formula : % Free testosterone l 6.11k2.38ilog
C-reactive protein was measured to ensure that no subject was suffering from an acute inflammatory illness, which may have affected hormone levels.
Total testosterone was measured by RIA (Coat-ACount ; Diagnostic Products Corp., Llanberris, Caernarfon, U.K.). Percentage bioavailable testosterone was assayed using an adaptation of the method of Tremblay and Dube [19] , where $H-labelled testosterone radioactive tracer was measured in the supernatant fraction following ammonium sulphate precipitation of SHBG. The concentration of bioavailable testosterone was then calculated from the percentage of the total steroid. Interassay variation was less than 8 % throughout the range of the assay. SHBG was measured by automated enzyme immunoassay (Immulite ; Diagnostic Products Corporation, Los Angeles, CA, U.S.A.). 17β-Oestradiol was measured using an ELISA assay from DRG Instruments GmbH, Germany. Cotinine was measured using the Cozart serum cotinine microplate enzyme immunoassay (Cozart Bioscience Ltd, Abingdon, Oxford, U.K.), to ensure accuracy of the self-reported smoking\non-smoking status of our subjects [20] . C-reactive protein was measured using the high-sensitivity Biostat\Diasys kit.
Statistical analysis
We estimated a sample size requirement of 25 people in each group in order to demonstrate a difference of at least one S.D. in androgen levels with 90 % power and 5 % significance. Data were inspected and analysed using the SPSS for Windows 95 computer package. Values for all parameters proved to be normally distributed except those for alcohol intake. Student's independent samples t test was used to compare mean values between the two groups for parametric data. The Mann-Whitney U test was used to analyse non-parametric data. Correlation coefficients were determined using Pearson's correlation statistic for parametric data. All results are expressed as meanspS.D. unless otherwise stated. Statistical significance was accepted when P 0.05.
RESULTS
Baseline characteristics of the two groups are shown in Table 1 . Cases were matched with controls for age and body mass index. Smokers had higher alcohol intake than controls, but this difference was not statistically significant. The large difference in cotinine levels demonstrates the reliability of the self-reported smoking\non-smoking status of our subjects. Table 2 shows the hormone profiles of the two groups. Levels of total and free testosterone were significantly higher in smokers compared with non-smokers ; however, the more accurate assessment of biologically active androgen status, bioavailable testosterone, was not significantly different. SHBG was higher in smokers than in non-smokers ; this difference approached statistical significance. There was no difference in 17β-oestradiol levels between the two groups.
Serum cotinine levels correlated positively with the reported number of cigarettes smoked daily (r l 0.40, P 0.05) and with levels of SHBG (r l 0.49, P 0.05), but not with any of the hormone levels analysed. None of the subjects had raised C-reactive protein, suggestive of concurrent acute inflammatory illness. Smoking and bioavailable testosterone 
DISCUSSION
The higher incidence of ischaemic heart disease in men compared with women, and reports of sudden cardiovascular death amongst male athletes abusing anabolic steroids, have led many to assume that androgens are detrimental to the male cardiovascular system [21, 22] . However, there is no direct evidence to support this theory, and there are numerous studies to support the contrary view. It has been convincingly demonstrated in male animal models that low androgen levels are associated with an increase in atheroma development, a phenomenon which is reversed by the administration of physiological levels of androgens [23] [24] [25] . In addition, a number of case-control studies have described an association between low androgen levels and excess cardiovascular risk in human males [15, [26] [27] [28] . This relationship is particularly marked when the bioavailable fraction of testosterone is assessed [16] . However, it is well recognized that case-control studies may be easily confounded by other factors. The effects of an excess of smokers in groups with coronary artery disease compared with controls in these studies may be an important confounding factor, with the demonstrated differences in levels of testosterone being only a consequence of cigarette smoking, not a risk factor for coronary heart disease itself. Previous work looking at the effects of smoking on androgen levels has produced conflicting results, which may be explained, in part, by difficulties in the accurate assessment of testosterone levels. Androgens display marked circadian fluctuations in plasma levels, and considerable intra-and inter-individual variability. In addition, much (65-80 %) of the circulating total testosterone is inactive and tightly bound to SHBG, whereas the biologically active fraction circulates either free (1-3 %) in the circulation or loosely bound (20-35 %) to albumin [29] . Levels of total testosterone can, therefore, be directly affected by changes in levels of SHBG and other plasma proteins. In addition, the direct immunoassay techniques used most commonly to measure free testosterone are also subject to variation due to differences in SHBG level [30] . Thus the measurement of total or free testosterone alone is insufficient to accurately assess the true impact of smoking on biologically active androgen status.
Two previous studies [1, 2] demonstrated significant falls in the levels of total testosterone amongst male smokers compared with non-smokers, but the levels of free, bioavailable testosterone, oestradiol or SHBG were not assessed in these patients. Conversely, many other studies [9] [10] [11] [12] [13] [14] have found the levels of total testosterone to be increased amongst male smokers. Two of these studies [10, 14] also reported an increase in the levels of free testosterone. However, in all but one of these studies [9] , no measurement of SHBG was made, and hence the testosterone levels were not adjusted for differences in plasma protein binding. The one study which did measure SHBG [9] demonstrated a significant increase in SHBG, but no significant change in ' albumin-bound testosterone,' suggesting the raised total testosterone levels were secondary to the raised SHBG. This is the only previous study to measure ' albumin-bound testosterone ', an approximation of the bioavailable fraction, and no significant difference was seen. Finally, a number of studies [3] [4] [5] [6] [7] [8] have reported no significant differences in the levels of total or free testosterone in male smokers versus non-smokers.
The present study demonstrates that plasma levels of biologically active testosterone, as assessed by the levels of bioavailable testosterone, do not differ between healthy male smokers and non-smokers, whereas levels of total and free testosterone are significantly higher in smokers. This discrepancy is a reflection of the difference in SHBG, which was higher in the smokers than in nonsmokers. We have also demonstrated that there was no significant difference in 17β-oestradiol levels, suggesting that the increased SHBG in the smokers is independent of changes in 17β-oestradiol levels.
SHBG was the only variable which significantly correlated with serum cotinine levels, a measure of cigarette smoking. This may indicate that smoking has a greater relative effect on the levels of SHBG than on the hormones themselves, supporting the suggestion that the observed differences in total and free testosterone in this and previous studies are due to changes in plasma binding capacity, rather than an effect of smoking on androgen levels. Plasma levels of SHBG may also be influenced by other clinical factors. Thyrotoxicosis and liver cirrhosis are both associated with elevated SHBG levels, whereas hypothyroidism and obesity have been linked with decreased SHBG levels [31, 32] . Although thyroid and liver function tests were not performed in this study, there was no clinical suspicion of thyroid or liver disease in any subject. Furthermore, subjects were matched by body mass index (Table 1) .
We conclude that accurate assessment of androgen status should include a measure of the biologically active fraction. In addition, it appears that smoking has no significant effect on the levels of bioavailable testosterone, and causes an increase in the measured levels of total testosterone. There is no evidence to suggest, therefore, that smoking status may be a confounding factor in association studies demonstrating a link between low levels of androgens and coronary heart disease.
